SABR for primary renal cell carcinoma: single-fraction or multiple-fraction?
- PMID: 36400104
- DOI: 10.1016/S1470-2045(22)00697-0
SABR for primary renal cell carcinoma: single-fraction or multiple-fraction?
Conflict of interest statement
I have received funds for research or education and honoraria for lectures from Varian, Hitachi, and BrainLab; honoraria for lectures from Elekta; and consulting fees from Varian.
Comment on
-
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).Lancet Oncol. 2022 Dec;23(12):1508-1516. doi: 10.1016/S1470-2045(22)00656-8. Epub 2022 Nov 16. Lancet Oncol. 2022. PMID: 36400098
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
